



Kroger  
Prescription  
Plans

# Adalimumab Update October 2023

## *Humira Market Analysis*

The first wave of adalimumab biosimilars launched in July 2023. Biosimilars are FDA approved medications that are expected to produce the same clinical results as safely and effectively as the biologic medicine that the biosimilar is comparable to, referred to as the “reference product.”

KPP offers unique management for biosimilars to include engagement with medical benefit providers, collaboration at our pharmacies, and advocating for a low net-cost strategy. Starting October 1, 2023, KPP will offer adalimumab biosimilars on the formulary as additional options for members. KPP will continue to evaluate the value biosimilars can deliver as more adalimumab biosimilars continue to come to the market in an effort to drive the lowest net cost for our clients and members

---

## Est \$38.4 billion

*in savings through 2025 due to adoption and use of biosimilars<sup>1</sup>*

<sup>1</sup>A. Mulcahy, et al. Am J Manag Care. July 2022.

800.917.4926

www.kpp-rx.com

## Formulary Management Strategy

1

### *Humira*

Reference Product

Manufactured by AbbVie

Preferred Specialty Brand with Prior Authorization

2

### *Hadlima*

Branded Biosimilar

Manufactured by Organon

Preferred Specialty Brand with Prior Authorization

3

### *Hyrimoz*

Branded Biosimilar

Manufactured by Sandoz

Preferred Specialty Brand with Prior Authorization

4

### *Adalimumab-ADAZ*

Unbranded Biosimilar

Manufactured by Sandoz

Preferred Specialty Brand with Prior Authorization